Inovalon — Q2 2018 Earnings Presentation
30 slides from Inovalon's earnings presentation, Aug 1, 2018
Slide 1: Q2 2018 Earnings Supplement
Q2 2018 Earnings Supplement August 1, 2018
Slide 2: Cautionary Note Regarding Forward-Looking Statement
Cautionary Note Regarding Forward-Looking Statement Certain statements contained in this presentation constitute forward-looking statements within the meaning of, and are intended to be covered by the safe harbor provisions of, Section 27A of the Securities Act of 1933, as amended, and Section 21E o
Slide 3: Contents
Contents 1 Overview Inovalon ONE® Platform Capability 2 This presentation serves as a Expansion supplement to the Inovalon announcement August 1, 2018 pertaining to second quarter (Q2) of 2018 results 3 2018 Q2 Financials and guidance. 4 2018 FY Guidance INOV Q2 2018 Earnings Supplement (8.1.18) v1.
Slide 4: The Inovalon ONE Platform
Payers Pharma Devices Diagnostics The Inovalon ONE® Platform Inovalon is a vertically integrated leader in cloud-based enablement of data-driven healthcare. Inovalon provides cloud-based, real-time Massive Advanced Intervention Data connectivity, analytics, intervention, and Data Assets Analytics To
Slide 5: Empowering Data-Driven Healthcare In Scale
Empowering Data-Driven Healthcare In Scale The reach of Inovalon’s platform has grown to touch the vast majority of the United States, able to empower the market’s largest data-driven healthcare initiatives. 100s Payers, Pharma, Device, and Diagnostics Organizations 252M+ Patients* 50K+ Provider Sit
Slide 6: Connectivity Expansion
Connectivity Expansion 200,000 PHYSICIANS CONNECTED 180,000 160,000 Inovalon’s direct-connect, real-time EHR connectivity continues to expand rapidly. 140,000 71% By the end of Q2 2018, Inovalon’s direct 120,000 Year-over-Year EHR connectivity had grown to more Expansion than 185,000 physicians, a y
Slide 7: MORE2 Registry Dataset Expansion
MORE2 Registry® 40 2 ® 39 MORE REGISTRY DATASET GROWTH Dataset 38 37 36 35 34 Expansion 33 32 31 30 Inovalon’s primary-source datasets continue to 29 Patient Count Medical Event Count 28 expand rapidly. As of the end of Q2 2018, the 27 26 260 MORE2 Registry® dataset contained more than 25 250 24 240
Slide 8: Contents
Contents 1 Overview Inovalon ONE® Platform Capability 2 This presentation serves as a Expansion supplement to the Inovalon announcement August 1, 2018 pertaining to second quarter (Q2) of 2018 results 3 2018 Q2 Financials and guidance. 4 2018 FY Guidance INOV Q2 2018 Earnings Supplement (8.1.18) v1.
Slide 9: ScriptMed Cloud
ScriptMed™ Cloud ScriptMed™ Cloud brings to the Specialty Pharmacy marketplace a cloud native, SaaS-based enterprise-wide solution empowering a new generation of data-driven specialty pharmacy capabilities, delivering increased efficiency, lower operating costs, and improved patient outcomes and exp
Slide 10: ScriptMed Cloud Advanced Capabilities
• Sophisticated clinical protocols powered by patient-specific data and ScriptMed™ advanced analytics • Extensive connectivity with EHRs, HIEs, payer systems, and Cloud provider-sites to speed necessary data capture and authorization processes • Modular design allowing health plans and provider syst
Slide 11: CDEaaS
CDEaaS™ Inovalon’s Clinical Data Extraction as a Service (CDEaaS™) leverages the Inovalon ONE® Platform’s extensive real-time connectivity, datasets, and large-scale compute processing capacity to autonomously identify and aggregate medical record data faster, at lower costs, and with greater qualit
Slide 12: NLPaaS
NLPaaS™ Inovalon’s Natural Language Processing as a Service (NLPaaS™) leverages the Inovalon ONE® Platform’s highly adaptive, machine learning capabilities and billions of known medical events to transform unstructured clinical data into highly valuable, structured clinical data and analyze results
Slide 13: CDEaaS and NLPaaS benefits
™ • Faster: Results come back in minutes to hours, not weeks to months CDEaaS typically required by alternative, labor-based medical record collection approaches & ™ • More Comprehensive Results: Clients often are unaware of where NLPaaS patients’ clinical data actually resides - a problem solved by
Slide 14: Contents
Contents 1 Overview Inovalon ONE® Platform Capability 2 This presentation serves as a Expansion supplement to the Inovalon announcement August 1, 2018 pertaining to second quarter (Q2) of 2018 results 3 2018 Q2 Financials and guidance. 4 2018 FY Guidance INOV Q2 2018 Earnings Supplement (8.1.18) v1.
Slide 15: Subscription-Based Progression
Subscription-Based Progression Inovalon continues to transform its revenue stream to subscription-based platform offerings. In Q2 2018, Inovalon generated 78% of revenues from subscription-based platform offerings as compared to 66% in Q2 2017. Sequential organic subscription-based platform revenue
Slide 16: Adjusting for Non-comparable G&A
Adjusting for Non-comparable G&A General and administrative expenses increased $24.3M in Q2 2018 as compared to Q2 2017. The increase was driven by $11.2M in non- comparable items that do not otherwise relate to Inovalon’s ongoing performance, $11.5M in acquired G&A associated with the ABILITY and C
Slide 17: Contents
Contents 1 Overview Inovalon ONE® Platform Capability 2 This presentation serves as a Expansion supplement to the Inovalon announcement August 1, 2018 pertaining to second quarter (Q2) of 2018 results 3 2018 Q2 Financials and guidance. 4 2018 FY Guidance INOV Q2 2018 Earnings Supplement (8.1.18) v1.
Slide 18: Revenue Offering Mix
Revenue Offering Mix The following guidance, previously provided on May 8, 2018, is being reaffirmed. $568 - $593 $449.4 $437.3 $427.6 ~75% 53% 54% 66% 43% 34% 19% ~13% 12% 15% ~12% 4% 2015 2016 2017 2018G Services Legacy Solutions Subscription-Based Platform Offerings All numbers in millions. INOV
Slide 19: Revenue
Revenue The following guidance, previously provided on May 8, 2018, is being reaffirmed. $568 - $593 $449 2011 – 2018G $437 $428 13% CAGR $362 $300 $296 $240 2011 2012 2013 2014 2015 2016 2017 2018G Note: CAGR calculations undertaken to the mid-point of 2018 Guidance. All numbers in millions. INOV Q
Slide 20: Adjusted EBITDA
Adjusted EBITDA The Company is increasing its guidance regarding full-year 2018 Adjusted EBITDA. $166 - $176 $152 $134 2011 – 2018G 17% CAGR $108 $109 $100 $72 $58 36% 37% 35% 29% 24% 24% 23% 24% 2011 2012 2013 2014 2015 2016 2017 2018G % of Revenue Note: CAGR calculations undertaken to the mid-poin
Slide 21: Cash Flow From Operations
Cash Flow From Operations The following guidance, previously provided on May 8, 2018, is being reaffirmed. $104 - $115 (Non-GAAP) 1 $98 $90 - $100 $93 (GAAP) 1 2011 – 2018G $86 11% CAGR $66 $68 $54 $46 22% 24% 22% 22% 19% ~19% 18% 16% - ~18% 1 1 2011 2012 2013 2014 2015 2016 2017 2018G % of Revenue
Slide 22: CAPEX Returning Towards Historical Levels
CAPEX Returning Towards Historical Levels During the period Q3 2016 through Q1 2018, the Company elected to invest more than $40M into incremental development towards the launch of the Inovalon ONE® Platform. The period of this disproportional investment is now nearly complete and is increasingly be
Slide 23: 2018 Revenue Guidance Bridge
• Net Client Churn expected to be ~5 points in 2018 2018 Revenue • Client decisions in 2017 to withdraw from ACA markets, unrelated to the efficacy of Inovalon services, is a short-term headwind of ~8 points in 2018, most pronounced in 1H 2018 Guidance Bridge • Continued transition and expansion of
Slide 24: 2018 Adjusted EBITDA Margin Bridge
• The full gross margin benefit of an increasing mix of higher margin Platform 2018 Adjusted offerings, coupled with continued technology-enabled efficiencies and the ABILITY acquisition, is seen to be partially offset by one-time client ACA withdrawals EBITDA Margin • Efficiencies achieved in overh
Slide 25: Financial Guidance Table
Financial Guidance Table The Company is updating full-year 2018 financial guidance to reflect: 1) expenses incurred from one-time restructuring initiatives undertaken during the second quarter of 2018, 2) increased fair-value contingent consideration in the setting of strong performance during the s
Slide 26: Appendix
Appendix INOV Q2 2018 Earnings Supplement (8.1.18) v1.0.0 26
Slide 27: Reconciliation of Forward-Looking Guidance Adjusted EBITDA
Reconciliation of Forward-Looking Guidance Adjusted EBITDA Inovalon defines Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA) as net income or loss calculated in accordance with GAAP, adjusted for the impact of depreciation and amortization, realized losses on
Slide 28: Reconciliation of Forward-Looking Guidance Non-GAAP Net Income
Reconciliation of Forward-Looking Guidance Non-GAAP Net Income Inovalon defines Non-GAAP net income as net income or loss calculated in accordance with GAAP, adjusted to exclude tax-affected stock- based compensation expense, acquisition costs, restructuring expense, amortization of acquired intangi
Slide 29: Reconciliation of Non-GAAP Net Cash Provided By Operating Activities
Reconciliation of Forward-Looking Guidance Non-GAAP Net Cash Provided By Operating Activities Inovalon defines Non-GAAP net cash provided by operating activities as net cash provided by operating activities calculated in accordance with GAAP, adjusted to exclude certain acquisition costs, specifical
Slide 30: Healthcare Empowered
Healthcare Empowered® © 2018 by Inovalon. All rights reserved.